Market Overview

Merrimack Pharmaceuticals Falls Back To Support Following JPMorgan Downgrade

Share:
Merrimack Pharmaceuticals Falls Back To Support Following JPMorgan Downgrade

Merrimack Pharmaceuticals Inc (NASDAQ: MACK) shares are trading lower by $0.23 at $5.75 in Friday's session. The catalyst for the decline is downgrade from JPMorgan from Overweight to Neutral.

The downgrade comes a few weeks after the issue made a quick sprint from $4.51 to $6.62 in only three days back in late September.

After making the high, it consolidated in the lower $6 handle before falling under $6 on Tuesday, closing at $5.96 and has not been able to post a close above that level over the next two days.

Related Link: Merrimack Pharma Shares Resume Trade, Now Down 9%

The downgrade has taken the issue to an important support level. On September 23, it posted a low a low at $5.68 and has not been below that level since that day. At this time, the intra-day low stands at $5.71 and the issue has struggled to distance itself from it.

If that level is breached, based on daily levels, the next major support level may not come in until its September 22 low at $5.10.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for MACK

DateFirmActionFromTo
Oct 2018MaintainsNeutralNeutral
Jun 2018MaintainsNeutralNeutral
Jun 2018DowngradesNeutralUnderweight

View More Analyst Ratings for MACK
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Downgrades Health Care Technicals Intraday Update Analyst Ratings

 

Related Articles (MACK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NVDACascendMaintains240.0
NXTCBank of AmericaReiterates89.0
RNRJP MorganAssumes173.0
CARBNorthlandDowngrades23.0
GLIBACitiUpgrades80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Lexicon Pharma Offers 'A 2-Part Story With Upside Prospects'

Kroger Buying Whole Foods Would Be 'Uncharacteristic' Says Citi